Gastroenterology Division, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Wang-Lang Road, Bangkok 10700, Thailand.
Gastroenterology and Hepatology Unit, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Kanchanawanich Road, Songkhla 90110, Thailand.
Clin Liver Dis. 2021 Nov;25(4):741-762. doi: 10.1016/j.cld.2021.06.004. Epub 2021 Jul 29.
Pegylated interferon-alpha therapy is one of the first-line chronic hepatitis B treatment. Finite treatment duration, absence of drug resistance, delayed response, and higher hepatitis B surface antigen loss than nucleos(t)ides analog therapy are the advantages of pegylated interferon-alpha treatment. Common side effects and subcutaneous injections requirement limit its use. Identifying patients likely to respond to pegylated interferon-alpha and optimizing treatment is reasonable. Motivating patients to complete the 48-week treatment is necessary. Treatment is stopped or switched to other treatment strategies in patients with stopping rule criteria. Combination therapy with nucleos(t)ides analog may improve response, but remains controversial.
聚乙二醇干扰素-α治疗是慢性乙型肝炎的一线治疗方法之一。聚乙二醇干扰素-α治疗的优势在于有限的治疗期限、无耐药性、延迟应答以及比核苷（酸）类似物治疗有更高的乙型肝炎表面抗原丢失率。常见的副作用和需要皮下注射限制了其应用。识别可能对聚乙二醇干扰素-α治疗有反应的患者并优化治疗是合理的。需要激励患者完成 48 周的治疗。对于符合停药标准的患者，治疗会停止或转换为其他治疗策略。核苷（酸）类似物联合治疗可能会提高应答率，但仍存在争议。
